Report cover image

Japan Compounded Sterile Preparations Market - 2024-2033

Publisher DataM Intelligence 4Market Research LLP
Published Mar 05, 2026
Length 182 Pages
SKU # DTAM21122363

Description

Japan Compounded Sterile Preparations Market Overview:
The Japan Compounded Sterile Preparations Market was valued at US$ 129 Million in 2024 and is anticipated to reach US$ 227.37 Million by 2033, at a CAGR of 0.065 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Japan Compounded Sterile Preparations Market.

This report delivers a comprehensive overview of the Japan Compounded Sterile Preparations Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Compounded Sterile Preparations Market. The Japan Compounded Sterile Preparations Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Japan Compounded Sterile Preparations Market Scope:
By Dosage Form
• Injectables
• Infusion Solutions
• Ophthalmic Solutions
• Topical Sterile Gels & Preparations

By Route of Administration
• Intravenous (IV)
• Intramuscular (IM)
• Subcutaneous (SC)
• Ocular

By Therapeutic
• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Hormonal Therapy
• Others

By Compound Risk Level
• Low-Risk Sterile Compounding
• Medium-Risk Sterile Compounding
• High-Risk Sterile Compounding

By End-User
• Hospitals
• Specialty clinics
• Pharmacies
• Home Healthcare & Outpatient Settings

By Compounding Facility Type
• Hospital-Based Sterile Compounding Units
• Independent Compounding Pharmacies
• Outsourcing Sterile Compounding Facilities

By Preparation Type
• Ready-to-Administer (RTA) Preparations
• Total Parenteral Nutrition (TPN) Admixtures
• Hazardous Drug Compounding
• Patient-Specific Customized Doses

Key Players
• Nichi-Iko Pharmaceutical Co., Ltd.
• FRESENIUS KABI AG
• Astellas Pharma Inc.
• Sato Pharmaceutical Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Chugai Pharmaceutical Co., Ltd.
• Daiichi Sankyo Company, Limited
• Baxter International, Inc.
• Vetter Pharma-Fertigung GmbH & Co. KG

Major Highlights
This report delivers a comprehensive overview of the Japan Compounded Sterile Preparations Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Compounded Sterile Preparations Market. The Japan Compounded Sterile Preparations Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

182 Pages
1. Definition and Overview
1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period
2. Executive Summary
2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Strong demand for ready-to-administer (RTA) sterile injectables
3.1.1.2. Growth in home infusion and outpatient IV treatments
3.1.1.3. Hospital automation and investment in aseptic compounding technology
3.1.2. Restraints
3.1.2.1. Strict regulatory compliance requirements increasing approval and audit burden
3.1.2.2. Short shelf life of compounded sterile products limiting distribution flexibility
3.1.3. Opportunity
3.1.3.1. Strategic outsourcing of sterile compounding by hospitals to specialized providers
3.1.3.2. Integration of automation and robotic aseptic compounding systems
3.1.3.3. Partnerships with biotech companies for biologics handling and reconstitution
3.1.4. Trends
3.1.4.1. Shift toward Ready-to-Administer (RTA) Sterile Products to improve safety and reduce medication errors
3.1.4.2. Adoption of Automated Aseptic Compounding Systems and robotics
3.1.5. Impact Analysis
4. Industry Analysis
4.1. Porter’s Five Force Analysis – Japan Compounded Sterile Preparations Market
4.2. Geopolitical & Supply Chain Exposure
4.3. Social & Patient-Centric Factors
4.4. Economic Factors
4.5. Pricing Analysis
4.6. Regulatory Analysis
4.7. Go-To-Market (GTM) Strategy
4.8. Innovation & R&D Trends
4.9. Sustainability and ESG Analysis
4.10. Sterile Injectable Generic Participants
4.11. Buyer Decision Criteria & Adoption Drivers
4.12. DMI Opinion – Strategic Outlook for the Japan Compounded Sterile Preparations Market
5. By Dosage Form
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
5.1.2. Market Attractiveness Index, By Dosage Form
5.2. Injectables*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Infusion Solutions
5.4. Ophthalmic Solutions
5.5. Topical Sterile Gels & Preparations
6. By Route of Administration
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
6.1.2. Market Attractiveness Index, By Route of Administration
6.2. Intravenous (IV)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Intramuscular (IM)
6.4. Subcutaneous (SC)
6.5. Ocular
7. By Therapeutic
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic
7.1.2. Market Attractiveness Index, By Therapeutic
7.2. Oncology*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Infectious Diseases
7.4. Cardiovascular Diseases
7.5. Hormonal Therapy
7.6. Others
8. By Compound Risk Level
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Compound Risk Level
8.1.2. Market Attractiveness Index, By Compound Risk Level
8.2. Low-Risk Sterile Compounding*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Medium-Risk Sterile Compounding
8.4. High-Risk Sterile Compounding
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty clinics
9.4. Pharmacies
9.5. Home Healthcare & Outpatient Settings
10. By Compounding Facility Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Compounding Facility Type
10.1.2. Market Attractiveness Index, By Compounding Facility Type
10.2. Hospital-Based Sterile Compounding Units*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Independent Compounding Pharmacies
10.4. Outsourcing Sterile Compounding Facilities
11. By Preparation Type
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Preparation Type
11.1.2. Market Attractiveness Index, By Preparation Type
11.2. Ready-to-Administer (RTA) Preparations*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Total Parenteral Nutrition (TPN) Admixtures
11.4. Hazardous Drug Compounding
11.5. Patient-Specific Customized Doses
12. Competitive Landscape Analysis
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
12.4. Partner Identification Analysis
12.5. Investment & Funding Landscape
12.6. Strategic Alliances & Innovation Pipelines
13. Company Profiles
13.1. Nichi-Iko Pharmaceutical Co., Ltd.*
13.1.1. Company Overview
13.1.2. Dosage Form Portfolio
13.1.3. Revenue Analysis
13.1.4. Pricing Analysis
13.1.5. SWOT Analysis
13.1.6. Recent Developments
13.1.6.1. Major Deals
13.1.6.2. M&A
13.1.6.3. Collaboration
13.1.6.4. Acquisition
13.1.6.5. Joint Ventures
13.1.6.6. Innovations
13.1.7. Recent News
13.1.7.1. Events
13.1.7.2. Conferences
13.1.7.3. Symposiums
13.1.7.4. Webinars
13.2. FRESENIUS KABI AG
13.3. Astellas Pharma Inc.
13.4. Sato Pharmaceutical Co., Ltd.
13.5. Takeda Pharmaceutical Company Limited
13.6. Chugai Pharmaceutical Co., Ltd.
13.7. Daiichi Sankyo Company, Limited
13.8. Baxter International, Inc.
13.9. Fresenius Kabi AG
13.10. Vetter Pharma-Fertigung GmbH & Co. KG (LIST NOT EXHAUSTIVE)
14. Japan Compounded Sterile Preparations Market – Research Methodology
14.1. Research Data
14.1.1. Secondary Data
14.1.2. Primary Data
14.1.3. CAGR Analysis
14.2. Market Size Estimation Methodology
14.2.1. Bottom-Up Approach
14.2.2. Top-Down Approach
14.3. Market Breakdown & Data Triangulation
14.4. Research Assumptions
14.5. Limitations
15. Appendix
15.1. About Us and Services
15.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us